Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT + KarX-EC in Agitation Associated With Alzheimer's Disease (ADAGIO-3)
NCT06937229Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Jun 2029
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of xanomeline and trospium in agitation, sponsored by Bristol Myers Squibb. Primary endpoint: Treatment Emergent Adverse Events at 30 weeks. Started Dec 2025; status: recruiting.
02
Drugs
xanomelinetrospium
03
Conditions
agitation
Beyond the preview
Go deeper on NCT06937229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937229.